Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Public ClinicalTrials.gov record NCT03041311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study was a randomized, double-blinded, placebo-controlled design. Approximately, 100 patients were randomized to trilaciclib + E/P/A or placebo + E/P/A in the study.
Study identification
- NCT ID
- NCT03041311
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2017 (Actual)
- Primary completion
- Aug 17, 2018 (Actual)
- Completion
- Oct 29, 2020 (Actual)
- Last update posted
- Sep 25, 2025
2017 – 2020
United States locations
- U.S. sites
- 23
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| St. Jude Heritage Healthcare | Fullerton | California | 92835 | — |
| Loma Linda University | Loma Linda | California | 92350 | — |
| UCLA Medical Center - Santa Monica Hematology And Oncology | Santa Monica | California | 90404 | — |
| Redwood Regional Medical Group (RRMG) - Fountain Grove | Santa Rosa | California | 95403 | — |
| Singing River Health System | Whittier | California | 90603 | — |
| Piedmont Cancer Institute | Atlanta | Georgia | 30318 | — |
| Northside Hospital - Georgia Cancer Specialists | Atlanta | Georgia | 30341 | — |
| Joliet Oncology-Hematology Associates | Joliet | Illinois | 60435 | — |
| Horizon Oncology Center | Lafayette | Indiana | 47905 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| St. Louis Cancer Care, LLP, North County | Bridgeton | Missouri | 63044 | — |
| The Alvin J. Siteman Cancer Center - Center for Advanced Med | St Louis | Missouri | 63110-1094 | — |
| Summit Medical Group, P.A. | Morristown | New Jersey | 07962 | — |
| Northern Westchester Hospital | Mount Kisco | New York | 10549 | — |
| Trinity Health - Trinity CancerCare Center | Minot | North Dakota | 58701 | — |
| Oklahoma University - Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma | 73117 | — |
| Gibbs Cancer Center | Spartanburg | South Carolina | 29303 | — |
| Valley Cancer Associates | Harlingen | Texas | 78550 | — |
| Millennium Oncology | Houston | Texas | 77090 | — |
| Virginia Cancer Specialists | Arlington | Virginia | 22031 | — |
| Blue Ridge Cancer Care | Blacksburg | Virginia | 24060 | — |
| Fort Belvoir Community Hospital | Fort Belvoir | Virginia | 22060 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03041311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03041311 live on ClinicalTrials.gov.